America’s Healthcare Affordability Crisis in 2026: Rising Costs, Coverage Gaps, and the Search for Solutions

America’s Healthcare Affordability Crisis in 2026: Rising Costs, Coverage Gaps, and the Search for Solutions

The numbers tell a stark story. In 2026, millions of Americans are feeling the direct impact of rising healthcare costs—through higher premiums, larger deductibles, surprise medical bills, and the difficult calculus of choosing between needed care and other essentials. The expiration of enhanced Affordable Care Act subsidies has added fresh urgency to a problem that polls consistently rank among voters’ top concerns.

Understanding the dimensions of the affordability crisis—and what policymakers, providers, and patients are doing about it—is essential for navigating the healthcare landscape in 2026.

The Subsidy Cliff: What Happened to ACA Premiums

The most immediate shock to healthcare affordability came on January 1, 2026, when the enhanced premium tax credits (EPTCs) that had been subsidizing ACA marketplace plans expired. These enhanced subsidies, originally enacted during the pandemic and extended multiple times, had dramatically reduced out-of-pocket premium costs for millions of Americans.

According to KFF analysis, the expiration resulted in a “spike in costs for premiums.” While both Democrats and Republicans proposed legislation in late 2025 to mitigate the impact, none of the proposals gained sufficient bipartisan support to become law before the deadline.

The result: an estimated 3-5 million Americans lost coverage as marketplace plans became unaffordable, and millions more faced significantly higher premiums. The subsidy expiration has been particularly acute for middle-income families who earn too much to qualify for traditional ACA subsidies but relied on the enhanced credits to afford coverage.

Provider Pressures: The Other Side of the Cost Equation

While consumers feel the pain of rising costs, providers are squeezed from the other direction. The American Hospital Association reported in 2025 that “hospitals and health systems are squeezed by persistent economic challenges,” including rising labor costs, pharmaceutical expenses, and supply chain pressures.

Consolidation in the healthcare industry has further complicated the picture. A federal HHS report on consolidation found that market concentration among hospitals, physician practices, and insurers has contributed to higher prices without corresponding improvements in quality. With fewer competitors in many markets, large health systems wield significant pricing power in negotiations with insurers—costs that are ultimately passed on to consumers.

The Consumer Reality: Tough Choices

KFF polling in 2026 reveals the human dimension of the affordability crisis. Americans report:

• Skipping or postponing needed medical care due to cost
• Difficulty paying medical bills, with medical debt remaining a leading cause of bankruptcy
• Rationing prescription medications—splitting pills, skipping doses, or not filling prescriptions
• Choosing between healthcare spending and other necessities like housing and food

The Harvard Joint Center for Housing Studies noted that with costs for basic necessities like housing becoming less affordable, the burden of healthcare spending has compounded the financial strain on American households.

GLP-1 Drugs: The Affordability Paradox

Perhaps no category better illustrates the healthcare affordability paradox than GLP-1 weight loss medications. These drugs offer transformative health benefits—significant weight loss, reduced cardiovascular risk, improved metabolic health—but at a cost of $900 to $1,300 per month without insurance.

The tension between clinical value and financial sustainability has become a defining healthcare policy challenge. If even a fraction of the 100 million-plus Americans with obesity were prescribed these medications at current prices, the cost to the healthcare system would run into the hundreds of billions of dollars annually.

Encouragingly, market forces are beginning to respond. The approval of new competitors, including oral formulations like orforglipron, combined with government pressure for price transparency and the removal of rebates, is expected to drive prices down. Direct-to-consumer programs are also expanding access, bypassing traditional insurance channels.

Policy Responses: What’s Being Done

Several policy approaches are gaining traction in 2026:

• Drug price negotiation: Medicare’s new authority to negotiate drug prices—established by the Inflation Reduction Act—is beginning to show results, with negotiated prices for several high-cost drugs set to take effect.
• Price transparency rules: Hospital and insurer price transparency requirements are providing consumers with more information, though the impact on actual prices remains debated.
• State-level action: Several states are establishing prescription drug affordability boards, creating public option health plans, and capping out-of-pocket costs for insulin and other essential medications.
• Site-neutral payment: Bipartisan interest in site-neutral payment policies—which would pay the same amount for a service regardless of whether it is delivered in a hospital or a doctor’s office—continues to build.

What Consumers Can Do

While systemic solutions work their way through the policy process, consumers in 2026 have some practical options for managing healthcare costs:

• Compare prices using hospital price transparency tools and insurer cost estimators before scheduling procedures
• Explore telehealth options, which are often significantly less expensive than in-person visits
• Ask about cash-pay discounts, which can sometimes be cheaper than using insurance
• Review medical bills carefully for errors—studies suggest a significant percentage of bills contain mistakes
• Consider health savings accounts (HSAs) if eligible, which offer triple tax advantages for healthcare spending

The healthcare affordability crisis is not a single problem with a single solution. It is a complex interplay of market dynamics, policy choices, and structural features of the American healthcare system. What is clear in 2026 is that the status quo is unsustainable—and that patients, providers, and policymakers alike are increasingly unwilling to accept it.